A Dose Escalating Phase I Study, Double-blind, Randomized, Placebo-controlled for Examining the Safety and Tolerability to a Prophylactic HIV-1 Vaccine Called MYM-V101, Administered i.m. in Combination With i.n. Administrations to Healthy Female Subjects

Trial Profile

A Dose Escalating Phase I Study, Double-blind, Randomized, Placebo-controlled for Examining the Safety and Tolerability to a Prophylactic HIV-1 Vaccine Called MYM-V101, Administered i.m. in Combination With i.n. Administrations to Healthy Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2015

At a glance

  • Drugs MYM V101 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Sponsors Mymetics Corporation
  • Most Recent Events

    • 21 Feb 2013 Mymetics Corporation has reported that results were published in PLOS ONE.
    • 12 Jul 2012 Actual end date (1 Sep 2010) added as reported by ClinicalTrials.gov.
    • 26 May 2011 Results reported in a Mymetics Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top